Rodman & Renshaw started coverage on shares of Actuate Therapeutics (NASDAQ:ACTU – Free Report) in a research report sent to investors on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.
Several other research firms have also recently issued reports on ACTU. HC Wainwright reaffirmed a “buy” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Wednesday, June 24th. Finally, Wall Street Zen cut Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Actuate Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.67.
Read Our Latest Stock Report on ACTU
Actuate Therapeutics Stock Performance
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). On average, analysts forecast that Actuate Therapeutics will post -0.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. ABS Direct Equity Fund LLC purchased a new stake in Actuate Therapeutics in the fourth quarter worth approximately $40,000. Deutsche Bank AG raised its stake in Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after buying an additional 8,051 shares during the last quarter. Barclays PLC raised its stake in Actuate Therapeutics by 68.6% during the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after buying an additional 6,081 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Actuate Therapeutics by 61,068.0% during the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock valued at $93,000 after buying an additional 15,267 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Actuate Therapeutics during the 4th quarter valued at $102,000.
About Actuate Therapeutics
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.
Recommended Stories
- Five stocks we like better than Actuate Therapeutics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
